Emerging therapies and future directions in targeting the tumor stroma and immune system in the treatment of pancreatic adenocarcinoma

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Pancreatic adenocarcinoma is typically refractory to conventional treatments and associated with poor prognosis. While therapeutic advances over the past several years have improved patient outcomes, the observed benefits have been modest at best, highlighting the need for continued development of alternate treatment strategies. The tumor microenvironment has been identified as being integral to oncogenesis through its direct effect on cellular pathway communication, immune inhibition, and promoting chemo-resistance. A more in depth understanding of the biology of the disease, in addition with our ability to develop more effective novel therapies have led to ongoing studies that are investigating several promising treatment options in this disease. Herein, we highlight and review the therapeutic landscape in pancreatic adenocarcinoma.

Original languageEnglish (US)
Article number193
JournalCancers
Volume10
Issue number6
DOIs
StatePublished - Jun 11 2018

Fingerprint

Immune System
Adenocarcinoma
Neoplasms
Therapeutics
Aptitude
Tumor Microenvironment
Direction compound
Carcinogenesis
Communication

Keywords

  • Desmoplasia
  • Immunotherapy
  • Microenvironment
  • Novel targeted therapies
  • Pancreatic adenocarcinoma
  • Stroma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{976e27b3c3d745c8bd53501f1f205da8,
title = "Emerging therapies and future directions in targeting the tumor stroma and immune system in the treatment of pancreatic adenocarcinoma",
abstract = "Pancreatic adenocarcinoma is typically refractory to conventional treatments and associated with poor prognosis. While therapeutic advances over the past several years have improved patient outcomes, the observed benefits have been modest at best, highlighting the need for continued development of alternate treatment strategies. The tumor microenvironment has been identified as being integral to oncogenesis through its direct effect on cellular pathway communication, immune inhibition, and promoting chemo-resistance. A more in depth understanding of the biology of the disease, in addition with our ability to develop more effective novel therapies have led to ongoing studies that are investigating several promising treatment options in this disease. Herein, we highlight and review the therapeutic landscape in pancreatic adenocarcinoma.",
keywords = "Desmoplasia, Immunotherapy, Microenvironment, Novel targeted therapies, Pancreatic adenocarcinoma, Stroma",
author = "Daniel Ahn and Ramanathan, {Ramesk K} and Tanios Bekaii-Saab",
year = "2018",
month = "6",
day = "11",
doi = "10.3390/cancers10060193",
language = "English (US)",
volume = "10",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "6",

}

TY - JOUR

T1 - Emerging therapies and future directions in targeting the tumor stroma and immune system in the treatment of pancreatic adenocarcinoma

AU - Ahn, Daniel

AU - Ramanathan, Ramesk K

AU - Bekaii-Saab, Tanios

PY - 2018/6/11

Y1 - 2018/6/11

N2 - Pancreatic adenocarcinoma is typically refractory to conventional treatments and associated with poor prognosis. While therapeutic advances over the past several years have improved patient outcomes, the observed benefits have been modest at best, highlighting the need for continued development of alternate treatment strategies. The tumor microenvironment has been identified as being integral to oncogenesis through its direct effect on cellular pathway communication, immune inhibition, and promoting chemo-resistance. A more in depth understanding of the biology of the disease, in addition with our ability to develop more effective novel therapies have led to ongoing studies that are investigating several promising treatment options in this disease. Herein, we highlight and review the therapeutic landscape in pancreatic adenocarcinoma.

AB - Pancreatic adenocarcinoma is typically refractory to conventional treatments and associated with poor prognosis. While therapeutic advances over the past several years have improved patient outcomes, the observed benefits have been modest at best, highlighting the need for continued development of alternate treatment strategies. The tumor microenvironment has been identified as being integral to oncogenesis through its direct effect on cellular pathway communication, immune inhibition, and promoting chemo-resistance. A more in depth understanding of the biology of the disease, in addition with our ability to develop more effective novel therapies have led to ongoing studies that are investigating several promising treatment options in this disease. Herein, we highlight and review the therapeutic landscape in pancreatic adenocarcinoma.

KW - Desmoplasia

KW - Immunotherapy

KW - Microenvironment

KW - Novel targeted therapies

KW - Pancreatic adenocarcinoma

KW - Stroma

UR - http://www.scopus.com/inward/record.url?scp=85048465504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048465504&partnerID=8YFLogxK

U2 - 10.3390/cancers10060193

DO - 10.3390/cancers10060193

M3 - Review article

VL - 10

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 6

M1 - 193

ER -